Abstracts Archive - Page 164 of 2607 - ACR Meeting Abstracts

Abstract Number: 0595 • ACR Convergence 2025
Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration
Rangi Kandane-Rathnayake¹, Yi-Hsing Chen², Alberta Hoi³, Vera Golder⁴, Worawit Louthrenoo⁵, Jiacai Cho⁶, Aisha Lateef⁷, Laniyati Hamijoyo⁸, Shue Fen Luo⁹, Yeong-Jian Jan Wu¹⁰, Chiu Wai Shirley Chan¹¹, Leonid Zamora¹², Yasuhiro Katsumata¹³, Sargunan Sockalingam¹⁴, Zhanguo Li¹⁵, Haihong Yao¹⁵, BMDB Basnayake¹⁶, Yih Jia Poh¹⁷, Yanjie Hao¹⁸, Zhuoli Zhang¹⁹, Madelynn Chan²⁰, Jun Kikuchi²¹, Yuko Kaneko²², Tsutomu Takeuchi²³, Shereen Oon²⁴, Kristine Ng²⁵, Sang-Cheol Bae²⁶, Cherica Tee²⁷, Michael Tee²⁷, Nicola Tugnet²⁸, Sean O’Neill²⁹, Geraldine Hassett³⁰, Fiona Goldblatt³¹, Naoaki Ohkubo³², Yusuke Miyazaki³², Mark Sapsford³³, Yoshiya Tanaka³⁴, Sandra Navarra³⁵, Chak Sing Lau³⁶, Mandana Nikpour³⁷ and Eric Morand³⁸, ¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ²Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ³Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ⁴Monash University, Clayton, Australia, ⁵Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ⁷Woodlands Health, Singapore, Singapore, ⁸Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ⁹Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁰Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan (Republic of China), ¹¹Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ¹²University of Santo Tomas Hospital, Manila, Philippines, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴University of Malaya Medical Center, Kuala Lumpur, Malaysia, ¹⁵Peking University People's Hospital, Beijing, China (People's Republic), ¹⁶National Hospital Kandy, Kandy, Sri Lanka, ¹⁷Singapore General Hospital, Singapore, Singapore, ¹⁸St Vincent’s Hospital Melbourne, Fitzroy, Australia, ¹⁹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²⁰Tan Tock Seng Hospital, Singapore, Singapore, ²¹Keio University, Tokyo, Japan, ²²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²³Saitama Medical University and Keio University, Tokyo, Japan, ²⁴St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia, ²⁵Health New Zealand Waitemata, Te Whatu Ora, Auckland, New Zealand, ²⁶Hanyang University Medical Center, Seoul, South Korea, ²⁷University of the Philippines, Manila, Philippines, ²⁸Health New Zealand Auckland, Te Whatu Ora (Auckland District Health Board), Auckland, New Zealand, ²⁹The University of Sydney, Sydney, Australia, ³⁰Liverpool Hospital, NSW, Liverpool, Australia, ³¹Flinders Medical Centre, Bedford park, Australia, ³²University of Occupational and Environmental Health, Kitakyushu, Japan, ³³Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital),, Auckland, New Zealand, ³⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³⁵University of Santo Tomas, Manila, Philippines, ³⁶The University of Hong Kong, Hong Kong, Hong Kong, ³⁷University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia, ³⁸Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia
Background/Purpose: Treat-to-target (T2T) states in SLE, such as the Lupus Low Disease Activity State (LLDAS) and remission (REM) as defined by the Definitions of Remission…
Abstract Number: 0705 • ACR Convergence 2025
Multimodal Imaging Evaluation of Patients with Raynaud’s Phenomenon meeting the Criteria for “Early” Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study
Ramona Govender¹, Elvis Hysa², Rosanna Campitiello³, Steven Wallaert¹, Matthias Vandycke¹, Emanuele Gotelli³, Tessa Du Four¹, Maurizio Cutolo⁴ and Vanessa Smith⁵, ¹University of Ghent, Ghent, Belgium, ²University of Genoa, Genoa, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genova, Genova, Italy, ⁵Ghent University Hospital, Gent, Belgium
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disorder. To date, no comparative multi-modal imaging data exist for precursor patients, those with Raynaud’s phenomenon (RP)…
Abstract Number: 0716 • ACR Convergence 2025
Utility of Follow-Up Cardiac Magnetic Resonance Imaging In Patients With Eosinophilic Granulomatosis With Polyangiitis
Chelsea Cheng¹, Justine Lafleur-Careau², Navneet Kang¹, Medha Soowamber³ and Christian Pagnoux³, ¹Mount Sinai Hospital, Toronto, Canada, ²Mount Sinai Hospital, Saint-Augustin-de-Desmaures, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystem disorder characterized by asthma, rhinitis, peripheral blood eosinophilia, and necrotizing vasculitis of small vessels. Cardiac…
Abstract Number: 0629 • ACR Convergence 2025
Characterizing Arthritis Subtypes in SLE: Prevalence, Clinical Features, and the Role of Type I Interferon Signatures
Pankti Mehta¹, Fadi Kharouf², Virginia Carrizo Abarza³, Qixuan Li⁴, Dafna D. Gladman⁵, Zahi Touma⁶ and Laura Whitall Garcia⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: We aimed to study the prevalence of subtypes of lupus arthritis and determine their association with clinical features, serology, and type I interferon signature.Methods:…
Abstract Number: 0721 • ACR Convergence 2025
Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Mats Junek¹, Sara Choi², Stephanie Garner³, Saara Rawn⁴, David Cuthbertson⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Ulrich Specks¹³, Kenneth Warrington¹³, Gerard Cox¹, Nader Khalidi¹⁴ and Peter Merkel⁸, ¹St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ²Queen's University, Kingston, ON, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴NOSM School of Medicine, Sudbury, ON, Canada, ⁵University of South Florida, Tampa, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic, Rochester, MN, ¹⁴McMaster University, Hamilton, ON, Canada
Background/Purpose: There is limited knowledge of the epidemiology and complications of pulmonary manifestations in ANCA-associated vasculitis (AAV). This analysis focused describing the range of pulmonary…
Abstract Number: 0895 • ACR Convergence 2025
Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial
FRANK BUTTGEREIT¹, Kevin Winthrop², Leonard Calabrese³, Ivan Lagunes⁴, Aditi Kadakia⁵, Ana Romero⁶, Shaofei Zhao⁴, Weihan Zhao⁴, Arathi Setty⁴ and Jeffrey Curtis⁷, ¹Charité University Medicine Berlin, Berlin, Berlin, Germany, ²Oregon Health & Science University, Portland, OR, ³Cleveland Clinic, Cleveland, OH, ⁴Abbvie Inc, North Chicago, IL, ⁵AbbVie Inc, Woburn, MA, ⁶AbbVie, Barcelona, Spain, ⁷University of Alabama at Birmingham, Birmingham
Background/Purpose: This study assessed the occurrence of adverse events of serious infections, herpes zoster, and opportunistic infection during concomitant treatment with GCs and after GC…
Abstract Number: 0659 • ACR Convergence 2025
Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
Ivette Casafont-Solé¹, Judit Font-Urgelles¹, Iñigo Rúa-Figueroa², Andrea Hernández-martín³, Tarek Salman Montes⁴, Marta De la Rubia Navarro⁵, Maria Piqueras García⁶, Sandra Garrote Corral⁷, EVA GLORIA TOMERO MURIEL⁸, Elena De la Mata Pinilla⁹, Belén Álvarez Rodríguez¹⁰, Julia Martínez Barrio¹¹, José Gomez-Puerta¹², Paola Vidal-Montal¹³, Eleonora Penzo¹⁴, Consuelo Ramos Giraldez¹⁵, Francisco Javier Novoa¹⁶, Vicenç Torrente-Segarra¹⁷, Jorge Juan Fragío Gil¹⁸, Leyre Riancho¹⁹ and Irene Altabás-González²⁰, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ⁴Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ⁵Hospital de La Fe, Valencia, ⁶Servicio Murciano de Salud, Murcia, Spain, ⁷Hospital Ramón y Cajal, Madrid, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital ¹² de Octubre, Madrid, ¹⁰Hospital de Áraba, áraba, Spain, ¹¹Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ¹²Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ¹³Rheumatology. Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, ¹⁴Hospital Vall d'Hebrón, Barcelona, Spain, ¹⁵Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ¹⁶Hospital Insular de Gran Canaria, Las palmas, ¹⁷Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ¹⁸Hospital General Universitario, Valencia, Spain, ¹⁹Hospital de Sierrallana, Torrelavega, ²⁰Complejo Hospitalario de Vigo, Vigo, Spain
Background/Purpose: Human papillomavirus (HPV) is responsible for 99.7% of cervical neoplasms and is the fourth most common cancer among women worldwide. Patients with systemic lupus…
Abstract Number: 0908 • ACR Convergence 2025
E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
Hrishikesh Mehta¹, Vijayashree Mysore¹, Chih-Hsing Chou¹, Lizhi Cao¹, Rui Liu², Tianrui Fan², Jijun Yuan², James Broderick¹ and Li Peng¹, ¹Palleon Pharmaceuticals, Waltham, MA, ²Shanghai Henlius Biotech, Shanghai, China (People's Republic)
Background/Purpose: Abnormal cell surface glycosylation has been observed in various autoimmune diseases, including systemic lupus erythematosus (SLE) and membranous nephropathy. Among these glycan modifications, sialoglycans…
Abstract Number: 0719 • ACR Convergence 2025
A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis
Ivana Stojkic¹, Arnon Arazi², Huijuan Song³, Pearlly Yan³, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Brad Rovin⁴, Stacy Ardoin¹ and Salem Almaani³, ¹Nationwide Children's Hospital, Columbus, OH, ²The Feinstein Institutes for Medical Research, Manhasset, ³OSU, Columbus, OH, ⁴The Ohio State University, Columbus, OH
Background/Purpose: ANCA-associated vasculitis frequently involves the kidneys causing glomerulonephritis (AAGN). Despite advances in treatment, many patients develop end-stage kidney disease. An improved understanding of the…
Abstract Number: 0896 • ACR Convergence 2025
Does complement product C5a and its receptor C5a receptor 1 play a role in giant-cell arteritis?
marc Corbera-bellalta¹, Nuria Farran-Centelles², Nina Visocnik¹, Sergio Prieto-Gonzalez³, Jose hernandez-rodriguez⁴, javier Marco-hernandez⁵, Georgina Espigol-Frigolé¹ and Maria Cid⁶, ¹Hospital Clínic. University of Barcelona. IDIBAPS., Barcelona, Spain, ²Autoimmune diseases, Barcelona, Spain, ³Hospital Clinic, Barcelona, Catalonia, Spain, ⁴Hospital Clinic. University of Barcelona. IDIBAPS, Barcelona, Catalonia, Spain, ⁵Hospital Clinic.University of Barcelona. IDIBAPS, Barcelona, Catalonia, Spain, ⁶Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Patients with giant-cell arteritis (GCA) are in an unmet need for reduction of GC exposure because of the high incidence of GC-related side effects…
Abstract Number: 0905 • ACR Convergence 2025
Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
Jinyang Li, Xiu Han, Yi Wang, Yiyi Li, Zhaoru Ma, Yang Li, Zhimin Zhang, Liu Li, Meng Ni, Jiangkun Bi, Xing Yang, Yao Xiong, Shuaixiang Zhou and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Immune reset, achieved through profound and sustained depletion of B cells and/or plasma cells, has demonstrated significant clinical efficacy in patients with severe and…
Abstract Number: 0617 • ACR Convergence 2025
Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
Kathryn Counts¹, Dulaney Wilson², Leon Furchtgott³ and Gary Gilkeson¹, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³SeraNova Bio, Boston, MA
Background/Purpose: Key features in the pathophysiology of SLE include cytokine dysregulation and autoantibody production. Traditional autoantibody testing in SLE is primarily limited to intracellular antigens…
Abstract Number: 0651 • ACR Convergence 2025
The ERβ Agonist, OSU-ERβ-012, Suppresses Systemic, Kidney and Heart Inflammation in a Chimeric Mouse Model of Systemic Lupus Erythematosus
Braden Zeno¹, Tim Alexandrov², Hongyu Yuan³, Shane Bruckner³ and Wael Jarjour², ¹Ohio State University, upper arlington, OH, ²The Ohio State University, Columbus, OH, ³OSU, Columbus, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that causes inflammation in many of the body’s tissues, including the skin, joints, lungs, kidneys…
Abstract Number: 0901 • ACR Convergence 2025
Data-Driven Metabolomics Identifies Diagnostic Signatures and Patient Subgroups in Systemic Autoimmune Disorders
Chary López pedrera¹, Antonio Perez-Campoamor², Gema Dolores García-Delgado³, Beatriz Vellón-García⁴, Adrián Llamas Urbano⁵, Laura Romero Zurita⁶, Pedro Ortiz Buitrago⁷, Christian Merlo⁸, Maria del carmen abalos-aguilera⁸, Nuria Barbarroja⁹, Verónica Bolón-Canedo¹⁰, MARIA ANGELES AGUIRRE ZAMORANO¹¹, Rafaela Ortega-Castro¹², Jerusalén Calvo¹³, Lourdes Ladehesa¹⁴, Marta Alarcon-Riquelme¹⁵, Alejandro Escudero-contreras⁸ and Carlos Pérez Sánchez¹⁶, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²STARTQUAKE S.L., Gijón, Spain/Research Center on Information and Communication Technologies (CITIC), University of A Coruña, A Coruña, Spain, Gijón, Spain, ³Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., Cordoba, Spain, ⁴Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ⁵Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain., Cordoba, Spain, ⁶Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Córdoba, Spain, ⁷Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁸Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁰Research Center on Information and Communication Technologies (CITIC), University of A Coruña, A Coruña, Spain, A coruña, Spain, ¹¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹⁴IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁵Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to characterize the metabolomic fingerprint of several systemic autoimmune diseases (SADs) and apply machine learning (ML) techniques to identify disease-specific biomarkers…
Abstract Number: 0903 • ACR Convergence 2025
Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling
Catherine Wioland¹, Corinne Vedrine², Caroline Walter¹, Fanny Marque², Thomas Dannequin², Melanie Cecci¹, David Buffet¹, Cindy Schmid¹, Elena Degl'Innocenti¹, Gautier Robert¹, Grazyna Wieczorek¹, David Schubert¹, Catriona Paape¹ and Isabelle Isnardi³, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ³Novartis, Gueberschwihr, France
Background/Purpose: B cells are key players in the pathogenesis of Sjögren’s disease (SjD) and other systemic auto-immune diseases, supporting B cell depletion as an attractive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].